SCHEMBL8511437

SCHEMBL8511437

C[C@H](NS(=O)(=O)c1ccccc1)C(F)(F)F

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.53
ALDH1A1 P00352 3/20 0.50
CYP1A2 P05177 1/20 0.50
CYP2C9 P11712 1/20 0.50
CYP2C19 P33261 1/20 0.50
MMP2 P08253 4/20 0.47
CA12 O43570 1/20 0.47
CA9 Q16790 1/20 0.47
CA14 Q9ULX7 1/20 0.47
ADAMTS4 O75173 2/20 0.46
NPSR1 Q6W5P4 1/20 0.44
MMP13 P45452 3/20 0.44
MMP3 P08254 2/20 0.44
MMP1 P03956 2/20 0.44
MMP9 P14780 2/20 0.44
MMP7 P09237 1/20 0.44
CA1 P00915 1/20 0.44
CA2 P00918 1/20 0.44
MMP8 P22894 1/20 0.44
SLC1A3 P43003 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17760488 1.00 SMN1; SMN2 (0.53) SMN1; SMN2ALDH1A1CYP1A2CYP2C9CYP2C19
SCHEMBL8510543 1.00 SMN1; SMN2 (0.53) SMN1; SMN2ALDH1A1CYP1A2CYP2C9CYP2C19
SCHEMBL5817710 0.83 SMN1; SMN2 (0.54) SMN1; SMN2ALDH1A1CYP1A2CYP2C9CYP2C19
SCHEMBL587137 0.82 CA2 (0.57) ALDH1A1MMP2CA12CA9CA14
SCHEMBL587136 0.82 CA2 (0.57) ALDH1A1MMP2CA12CA9CA14
SCHEMBL578811 0.80 SLC1A3 (0.50) SLC1A3SLC1A2SLC1A1L3MBTL1ALOX5AP
SCHEMBL578868 0.80 SLC1A3 (0.50) SLC1A3SLC1A2SLC1A1L3MBTL1ALOX5AP
SCHEMBL578908 0.80 SLC1A3 (0.50) SLC1A3SLC1A2SLC1A1L3MBTL1ALOX5AP
SCHEMBL29509588 0.79 SMN1; SMN2 (0.54) SMN1; SMN2ALDH1A1CYP1A2CYP2C9CYP2C19
SCHEMBL945862 0.78 SMN1; SMN2 (0.61) SMN1; SMN2ALDH1A1CYP1A2CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108064224-B Amide-substituted thiazoles as modulators of Ror gamma t 詹森药业有限公司 2022-03-29 CN disclosed
US-9593108-B2 Compounds and methods for antiviral treatment PTC THERAPEUTICS, INC. (US) 2017-03-14 US disclosed
US-20120135999-A1 COMPOUNDS AND METHODS FOR ANTIVIRAL TREATMENT PTC THERAPEUTICS, INC. (US) 2012-05-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120135999-A1 COMPOUNDS AND METHODS FOR ANTIVIRAL TREATMENT EIF2AK2, MAVS, ZC3HAV1 SMN1; SMN2 3078/4885ALDH1A1 3538/4885CYP1A2 4149/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.